文献速递主动脉疾病

他汀类药物对急性B型主动脉夹层患者胸主动脉腔内修复术后预后的影响

Effect of Statins on the Prognosis After Thoracic Endovascular Aortic Repair for Patients With Acute Type B Aortic Dissection.
PubMed 文献 · J Endovasc Ther · 2024-12-19

该回顾性研究纳入2005年1月至2022年6月间645例急性B型主动脉夹层患者,按是否长期术后他汀治疗分为他汀组330例与非他汀组315例,并按入院LDL-C中位数分为高、低LDL-C组。他汀治疗显著降低全因死亡(3.03% vs 8.57%,p=0.002)、主动脉相关死亡(0.91% vs 3.81%,p=0.015)及主动脉相关不良事件(4.24% vs 11.11%,p=0.001),在高入院LDL-C患者中尤为明显。

要点

  • 他汀组全因死亡3.03% vs 非他汀组8.57%(p=0.002),主动脉相关死亡0.91% vs 3.81%(p=0.015)。
  • 他汀组主动脉相关不良事件4.24% vs 非他汀组11.11%(p=0.001)。
  • 他汀治疗与全因死亡、主动脉相关死亡及主动脉相关不良事件风险降低相关,尤其在高入院LDL-C患者中。

核心结论

  • 长期他汀治疗似乎可降低急性B型主动脉夹层患者胸主动脉腔内修复术后全因死亡和主动脉相关死亡风险,尤其在高入院LDL-C患者中。
  • 入院LDL-C较低的患者在随访期间主动脉相关死亡也有减少。
  • 他汀治疗还与随访期间较低的主动脉相关不良事件发生率相关,这些发现提示他汀可能对改善该人群长期预后至关重要。

研究设计与样本

  • 回顾性分析2005年1月至2022年6月间645例急性B型主动脉夹层患者,按是否长期术后他汀治疗分为他汀组330例与非他汀组315例。
  • 按入院LDL-C中位数水平进一步分为高LDL-C组和低LDL-C组,以评估他汀对胸主动脉腔内修复术后预后的影响。

主要发现

  • 队列平均年龄53.44±11.42岁,男性占81.71%。
  • 他汀治疗显著降低全因死亡(3.03% vs 8.57%,p=0.002)和主动脉相关死亡(0.91% vs 3.81%,p=0.015),尤其在高入院LDL-C患者中。
  • 他汀组主动脉相关不良事件发生率较低(4.24% vs 11.11%,p=0.001)。
  • Kaplan-Meier分析显示他汀降低全因死亡和主动脉相关不良事件的5年累积发生率(Log-rank p<0.05),校正后趋势持续。
  • 多因素Cox分析证实他汀治疗与全因死亡、主动脉相关死亡及主动脉相关不良事件风险降低相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the clinical efficacy of long-term statin therapy following thoracic endovascular aortic repair (TEVAR) in patients with acute type B aortic dissection (ATBAD). METHODS: We retrospectively analyzed data from 645 patients treated between January 2005 and June 2022, dividing them into Statin Group (n=330) and Non-statin Group (n=315) based on whether they received long-term postoperative statin therapy. Patients were further categorized based on median admission low-density lipoprotein cholesterol (LDL-C) levels into High and Low LDL-C Groups to assess the effect of statins on the prognosis of ATBAD patients after TEVAR. RESULTS: The cohort had an average age of 53.44±11.42 years old, and 81.71% were male. Statin therapy significantly reduced occurrences of all-cause death (3.03% vs 8.57%, p=0.002) and aorta-related death (0.91% vs 3.81%, p=0.015), particularly in patients with high admission LDL-C levels. In addition, patients with statin therapy had a lower incidence of aorta-related adverse events (ARAE) (4.24% vs 11.11%, p=0.001). Kaplan-Meier analysis indicated statins reduced 5-year cumulative incidence rates of all-cause death and ARAE (all Log-rank p<0.05). These trends were sustained after adjustment. Multivariate Cox analysis confirmed that statin therapy was associated with reduced risks of all-cause and aorta-related deaths, as well as ARAE. CONCLUSION: Long-term statin therapy appears to decrease the risk of all-cause and aorta-related death in ATBAD patients after TEVAR, particularly patients with high admission LDL-C levels. Patients with lower LDL-C levels at admission have a reduction of aorta-related death in the follow-up period. Statin therapy also was associated with a lower incidence of ARAE in follow-up. These findings suggest that statins might be crucial in improving long-term outcomes in this patient population.Clinical ImpactLong-term statin therapy administered to patients with acute type B aortic dissection (ATBAD) following thoracic endovascular aortic repair (TEVAR) demonstrates a substantial reduction in both all-cause and aorta-related mortality. Notably, this therapeutic benefit is most evident in patients presenting with elevated low-density lipoprotein cholesterol (LDL-C) levels at admission. Furthermore, statin therapy is associated with a decreased incidence of aorta-related adverse events during follow-up. These findings underscore the pivotal role of statin therapy in enhancing long-term clinical outcomes for ATBAD patients undergoing TEVAR, thereby contributing to improved patient care and prognosis.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Cheng J, Zhang Z, Wang Y, et al. Effect of Statins on the Prognosis After Thoracic Endovascular Aortic Repair for Patients With Acute Type B Aortic Dissection. J Endovasc Ther. 2024. PMID: 39698950. doi:10.1177/15266028241306356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。